ArticleVirology journal2026
A novel ORF127/ORF130 gene deletion Orf virus vaccine candidate: construction and evaluation.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Host-Orf virus interactions: A comprehensive review of pathogenesis and immune evasion mechanisms.Virulence · 2026Review
- Isolation and whole-genome characterization of an Orf virus strain from a goat in Binzhou, Shandong Province, China.Archives of virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundOrf is a zoonotic infectious disease caused by the Orf virus (ORFV), posing a serious threat to the health of ruminants and humans. Vaccination remains the most effective strategy for disease control. However, the limitations of conventional vaccines necessitate the development of safer and more efficient alternatives.
methodsBased on the previously attenuated Orf vaccine strain (HB-TS09F65) as the parental virus, two gene-deletion strains, rHB09-ΔORF127 and rHB09-ΔORF130, were successfully constructed by deleting the ORF130 and ORF127 genes via homologous recombination.
resultsIn vitro experiments demonstrated that both gene-deletion strains exhibited replication capacity and genetic stability comparable to their parental strains (vaccine and virulent strains). Compared with the parental strains, the two gene-deletion viruses showed reduced virulence. Immunogenicity studies of two gene-deleted virus strains demonstrated that they elicited humoral immune responses comparable to the parental virus, and significantly enhanced Th1-type cellular immune responses. Challenge experiments in a rabbit model demonstrated that rHB09-ΔORF127 and rHB09-ΔORF130 provided protection rates of 100% and 85.7%, respectively.
conclusionThe two gene-deletion strains exhibit efficient antigen production, favorable immunogenicity, improved safety, and effective protection, making them promising candidate strains for the development of a gene-deleted vaccine against Orf.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.